Cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 9, Issue 6, 2003, Pages 484-485

  Marshall, Bruce C ^a  

^a CYSTIC FIBROSIS FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; MACROLIDE; SALMETEROL;

BACTERIAL INFECTION; BURKHOLDERIA CEPACIA; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HUMAN; IMMUNOLOGY; INFECTION; INFLAMMATION; LUNG FUNCTION; PATHOPHYSIOLOGY; PSEUDOMONAS AERUGINOSA;

EID: 0142042488     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200311000-00006     Document Type: Editorial

References (5)

1. Fuchs HJ, Borowitz DS, Christiansen DH, et al.: Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994, 331:637-642.
2. Ramsey BW, Pepe MS, Quan JM, et al.: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999, 340:23-30.
3. Equi A, Balfour-Lynn IM, Bush A, et al.: Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002, 360:978.
4. Wolter J, Seeney S, Bell S, et al.: Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002, 57:212-216.
5. Saiman L, Marshall BC, Mayer-Hamblett M, et al.: Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA, in press.